Merus N.V. announced promising initial clinical data for its bispecific antibody petosemtamab in combination with standard treatment for colorectal cancer. The study showed a 100% response rate in left-sided mCRC and a 62% response rate in right-sided mCRC. Dr. Moh’d Khushman will present the updated data at a conference on October 24. Petosemtamab targets both EGFR and LGR5, offering new hope for patients with metastatic colorectal cancer. The safety profile of petosemtamab appears favorable, with no significant new safety concerns reported. Further research and development are ongoing to explore its potential as a groundbreaking treatment.

Read more at GlobeNewswire: Tussentijdse gegevens van Merus over petosemtamab bij